Table 1. Clinical and biological analyses.
| Control (n=7) | Sorafenib (n=7) | ARQ 092 (n=7) | Combination (n=7) | ANOVA p-values | ||
|---|---|---|---|---|---|---|
| Body Weight (g) | 290±7.4 | 291±2.0 | 270±6.0 | 274±5.6 | ns | |
| Liver | Weight (g) | 14.8±1.3 | 13.4±0.7 | 11.0±0.5* | 10.9±0.5**,# | 0.0026 |
| TG (g/L) | 28.9±4.4 | 30.5±3.4 | 29.1±3.0 | 30.1±2.1 | ns | |
| Blood | Albumin (g/dL) | 3.69±0.03 | 3.71±0.01 | 4.07±0.11*,## | 3.76±0.05 | 0.0046 |
| AFP (ng/mL) | 0.82±0.17 | 0.44±0.12 | 0.33±0.09* | 0.27±0.04* | 0.0151 | |
| AST (U/L) | 101.3±3.3 | 95.2±3.9 | 92.3±3.6 | 91.1±2.5 | ns | |
| ALT (U/L) | 73.1±5.2 | 73.0±3.9 | 67.6±6.3 | 68.4±2.2 | ns | |
| ALP (U/L) | 224±7.1 | 219±7.7 | 255±24.8 | 264±14.2 | ns | |
| GGT (U/L) | 21.5±3.8 | 15.9±2.8 | 13.3±1.9 | 7.4±1.4** | 0.0073 | |
| PT (s) | 16.3±0.4 | 18.7±1.8 | 16.7±0.2 | 16.5±0.4 | ns | |
| Total Bilirubin (mg/dL) | 0.21±0.01 | 0.18±0.01 | 0.16±0.01* | 0.17±0.01 | 0.0211 | |
| Creatinine (mg/dL) | 0.35±0.03 | 0.36±0.02 | 0.38±0.02 | 0.36±0.02 | ns | |
| GLU (mg/dL) | 128±3.4 | 142±4.3 | 153±4.7 | 142±4.8 | ns | |
| Cholesterol (mg/dL) | 86.6±6.5 | 84.9±4.0 | 102±7.3 | 88.7±5.1 | ns | |
| TG (g/L) | 62.2±11.5 | 75.1±11.2 | 60.2±7.7 | 67.7±10.1 | ns | |
Abbreviations: AFP, alphafetoprotein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; GGT, Gamma-glutamyl transpeptidase; PT, Prothrombin time. Values are means ± SE. Significant difference compared to control; *: p<0.05; **: p<0.01; ***: p<0.001; ****: p<0.0001. Significant difference between ARQ 092 and Sorafenib; ##: p<0.01.